Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Methods of treating Syndrome X with aliphatic polyamines|
|Abstract:||The invention relates to a method for treating Syndrome X, or inhibiting the onset of symptoms of Syndrome X in a patient, and includes administering a therapeutically effective amount of a salt of at least one alkylated and cross-linked polymer, or a copolymer thereof, the polymer salt formed as a product of the reaction of one or more polymers, or salts and copolymers thereof, having a repeat unit that is essentially: ##STR00001## where n is a positive integer and each R, independently, is H or a C.sub.1 C.sub.8 alkyl group; at least one aliphatic alkylating agent; and a cross-linking agent. Long term administration of the cross-linked polyamine salts of the invention increases HDL levels and decreases LDL levels in patients. The invention also provides for administration of the polymer salt colesevelam, in combination with an HMG-CoA reductase inhibitor; the combined administration is effective in further lowering serum total-cholesterol and LDL-cholesterol levels beyond that achieved by either agent alone.|
|Inventor(s):||Burke; Steven K. (Sudbury, MA), Donovan; Joanne M. (Needham, MA)|
|Assignee:||Genzyme Corporation (Cambridge, MA)|
|Filing Date:||Apr 17, 2002|
|Claims:||1. A method for treating Syndrome X in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of colesevelam or a pharmaceutically acceptable salt thereof, alone or in combination with an antihyperlipidemic agent; a plasma HDL-raising agent; an antihypercholesterolemic agent; an acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor; a cholesterol absorption inhibitor; a bile acid sequestrant anion exchange resin; an LDL (low density lipoprotein) receptor inducer; a fibrate; vitamin B.sub.6 (also known as pyridoxine) or a pharmaceutically acceptable salt thereof; vitamin B.sub.12; an anti-oxidant vitamin; an angiotensin II antagonist converting enzyeme inhibitor; or a platelet aggregation inhibitor. |
2. A method for treating Syndrome X in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of sevelamer or a pharmaceutically acceptable salt thereof.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.